Technical Analysis for ABEO - Abeona Therapeutics Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| B | 6.25 | -2.50% | -0.16 |
Earnings due: Nov 11
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Hammer Candlestick | Bullish | -2.50% | |
| Pocket Pivot | Bullish Swing Setup | -2.50% | |
| Bollinger Band Squeeze | Range Contraction | -2.50% | |
| BB Squeeze + Lower Band Touch | Range Contraction | -2.50% | |
| Lower Bollinger Band Touch | Weakness | -2.50% | |
| Fell Below 20 DMA | Bearish | -1.73% | |
| Bollinger Band Squeeze | Range Contraction | -1.73% | |
| Gapped Down | Weakness | -1.73% |
| Alert | Time |
|---|---|
| Possible NR7 | about 20 hours ago |
| Lower Bollinger Band Support | about 23 hours ago |
| Fell Below Lower Bollinger Band | about 23 hours ago |
| Hammer Candlestick Entry | about 24 hours ago |
| Rose Above Previous Day's High | about 24 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/11/2024
Abeona Therapeutics Inc. Description
Abeona Therapeutics, Inc., formerly PlasmaTech Biopharmaceuticals, Inc., is focused on developing and delivering gene therapy and plasma-based products for severe and rare diseases. The Company's lead program includes adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB). Its product pipeline includes ABO-101 (sc AAV9 NAGLU), which is used for the treatment of MPS III B; ABO-102 (sc AAV9 SGSH), which is used for the treatment of MPS III A; ABO-201 (sc AAV9 CLN3), which is used for the treatment of Juvenile Batten Disease (JBD); ABO-301 (AAV LK19 FANCC), which is used for the treatment of Fanconi Anemia (FA), and clustered, regularly interspaced short palindromic repeats/CRISPR associated protein 9 (CRISPR/Cas9) gene editing, which is used for treatment of other rare blood diseases. The Company offers two platforms: Salt Diafiltration (SDF) Process and Polymer Hydrogel Technology (PHT).
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Biology Emerging Technologies Molecular Biology Rare Diseases Gene Therapy Genetics Genetic Engineering Anemia CRISPR Genome Editing Adeno Associated Virus Cas9 Severe And Rare Diseases Blood Diseases Fanconi Anemia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.01 |
| 52 Week Low | 3.05 |
| Average Volume | 233,631 |
| 200-Day Moving Average | 5.66 |
| 50-Day Moving Average | 6.05 |
| 20-Day Moving Average | 6.48 |
| 10-Day Moving Average | 6.42 |
| Average True Range | 0.31 |
| RSI (14) | 48.19 |
| ADX | 22.06 |
| +DI | 15.42 |
| -DI | 18.00 |
| Chandelier Exit (Long, 3 ATRs) | 5.85 |
| Chandelier Exit (Short, 3 ATRs) | 6.97 |
| Upper Bollinger Bands | 6.75 |
| Lower Bollinger Band | 6.21 |
| Percent B (%b) | 0.08 |
| BandWidth | 8.44 |
| MACD Line | 0.09 |
| MACD Signal Line | 0.15 |
| MACD Histogram | -0.0591 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.63 | ||||
| Resistance 3 (R3) | 6.66 | 6.56 | 6.56 | ||
| Resistance 2 (R2) | 6.56 | 6.47 | 6.55 | 6.54 | |
| Resistance 1 (R1) | 6.41 | 6.41 | 6.36 | 6.38 | 6.52 |
| Pivot Point | 6.31 | 6.31 | 6.29 | 6.30 | 6.31 |
| Support 1 (S1) | 6.16 | 6.22 | 6.11 | 6.13 | 5.98 |
| Support 2 (S2) | 6.06 | 6.16 | 6.05 | 5.96 | |
| Support 3 (S3) | 5.91 | 6.06 | 5.94 | ||
| Support 4 (S4) | 5.88 |
